Claims for Patent: 9,149,530

Summary for Patent: 9,149,530

Title:	Compositions and methods for enhancing active agent absorption
Abstract:	Compositions and methods for enhancing the absorption of active agents across the mucosa of animal subjects are provided. Methods of administration and appropriate dosage forms are also provided.
Inventor(s):	Shih; Chung (Sandy, UT)
Assignee:	Nexus Pharma, Inc. (Salt Lake City, UT)
Application Number:	13/827,162
Patent Claims:	1. A composition, comprising: a) at least one active agent selected from the group consisting of a polypeptide, a hormone, a polysaccharide, prostaglandins, cyclosporin, cromolyn sodium, vancomycin, desferrioxamine and vitamins; and b) an absorption enhancer having the formula: ##STR00005## or a pharmaceutically acceptable salt thereof, wherein R.sub.1 is null, C.sub.1-C.sub.12 alkylene, C.sub.2-C.sub.12 alkenylene, arylene, or substituted alkylene, alkenylene, or arylene, said substituted alkylene, alkenylene, or arylene being substituted with N, O, S, or P; R.sub.2 is C.sub.1-C.sub.12 alkyl, C.sub.2-C.sub.12 alkenyl, aryl, or cycloalkyl; each R.sub.3 is independently hydrogen, C.sub.1-C.sub.12 alkyl, C.sub.2-C.sub.12 alkenyl, or aryl, or substituted alkyl, alkenyl, or aryl, said substituted alkyl, alkenyl, or aryl being substituted with N, O, S, or P; wherein the composition is in a dosage form configured to bring a therapeutically effective amount of the at least one active agent into effective contact with a mucosal surface of a subject. 2. The composition of claim 1, wherein the at least one active agent is selected from the group consisting of growth hormones, growth hormone releasing hormones, interferons, cytokines, insulins, insulin-like growth factors, heparins, calcitonins, erythropoetin, granulocyte-colony stimulating factor, atrial naturetic factor, antigens, monoclonal antibodies, somatostatin; protease inhibitors, adrenocorticotropin, gonadotropin releasing hormone, oxytocin, leutinizing hormone releasing hormone, follicle stimulating hormone, glucocerebrosidase, thrombopoietin, human granulocyte colony stimulating factor, valinomycin, cyclosporin, vasopressin, cromolyn sodium, vancomycin, parathyroid hormone, polyethylene glycol derivatives of these compounds, and combination thereof. 3. The composition of claim 1, wherein the moiety containing R.sub.1 is para on the aromatic ring with respect to the moiety containing R.sub.2. 4. The composition of claim 1, wherein the moiety containing R.sub.1 is meta on the aromatic ring with respect to the moiety containing R.sub.2. 5. The composition of claim 1, further comprising an enzyme inhibitor. 6. The composition of claim 1, wherein the active agent is selected from the group consisting of proteins, polypeptides, hormones, polysaccharides, carbohydrates, and combinations thereof. 7. The composition of claim 1, formulated into a dosage form selected from the group consisting of tablet, capsule, lozenge, liquid solution, liquid suspension, paste, gel, cream, powder, patch, and suppository. 8. The composition of claim 1, wherein the dosage form is a liquid solution or suspension. 9. The composition of claim 1, wherein the dosage form is a patch. 10. The composition of claim 1, wherein the dosage form is a suppository. 11. The composition of claim 1, formulated in an oral dosage form. 12. The composition of claim 1, wherein the dosage form comprises an additive selected from the group consisting of diluents, solubilizers, excipients, flavorants, taste masking agents, surfactants, buffering agents, preservatives, antioxidants, colorants, fillers, disintegrants, lubricants, glidants, plasticizers, ethanol, pore formers, propylene glycol, saccharides, polyethylene glycol, and combinations thereof. 13. A method of enhancing transmucosal absorption of active agents in a subject, comprising administering a composition to the subject so that the composition comes into effective contact with a mucosal surface of the subject, said composition comprising: a) at least one active agent selected from the group consisting of a polypeptide, a hormone, a polysaccharide, prostaglandins, cyclosporin, cromolyn sodium, vancomycin, desferrioxamine and vitamins; and b) an absorption enhancer having the formula: ##STR00006## or a pharmaceutically acceptable salt thereof, wherein R.sub.1 is null, C.sub.1-C.sub.12 alkylene, C.sub.2-C.sub.12 alkenylene, arylene, or substituted alkylene, alkenylene, or arylene, said substituted alkylene, alkenylene, or arylene being substituted with N, O, S, or P; R.sub.2 is C.sub.1-C.sub.12 alkyl, C.sub.2-C.sub.12 alkenyl, aryl, or cycloalkyl; each R.sub.3 is independently hydrogen, C.sub.1-C.sub.12 alkyl, C.sub.2-C.sub.12 alkenyl, or aryl, or substituted alkyl, alkenyl, or aryl, said substituted alkyl, alkenyl, or aryl being substituted with N, O, S, or P. 14. The method of claim 13, wherein the mucosal surface is selected from the group consisting of buccal, sublingual, nasal, rectal, pulmonary, ocular, or vaginal. 15. The method of claim 13, wherein the composition is administered orally. 16. The method of claim 13, wherein the composition is administered in a dosage form selected from the group consisting of tablet, capsule, lozenge, liquid solution, liquid suspension, paste, gel, cream, powder, patch, and suppository. 17. The method of claim 13, wherein the dosage form is a liquid solution or suspension. 18. The method of claim 13, wherein the dosage form is a tablet or capsule. 19. The method of claim 13, wherein the dosage form is a suppository. 20. The method of claim 13, wherein the dosage form is a cream. 21. The method of claim 13, wherein the active agent is selected from the group consisting of growth hormones, growth hormone releasing hormones, interferons, cytokines, insulins, insulin-like growth factors, heparins, calcitonins, erythropoetin, granulocyte-colony stimulating factor, atrial naturetic factor, antigens, monoclonal antibodies, somatostatin; protease inhibitors, adrenocorticotropin, gonadotropin releasing hormone, oxytocin, leutinizing hormone releasing hormone, follicle stimulating hormone, glucocerebrosidase, thrombopoietin, human granulocyte colony stimulating factor, valinomycin, cyclosporin, vasopressin, cromolyn sodium, vancomycin, parathyroid hormone, polyethylene glycol derivatives of these compounds, and combination thereof.

Details for Patent 9,149,530

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2026-05-22